We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-16.69%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.07B
AUM Growth
-$429M
Cap. Flow
+$142M
Cap. Flow %
6.88%
Top 10 Hldgs %
44.14%
Holding
87
New
6
Increased
22
Reduced
12
Closed
8

Top Buys

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$137M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$48.1M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$32.9M
4
RPTX
Repare Therapeutics
RPTX
+$28.7M
5
CGEM icon
Cullinan Oncology
CGEM
+$24.3M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$99.7M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$64.9M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$37.2M
4
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$14.6M
5
GBIO
Generation Bio
GBIO
+$8.15M

Sector Composition

Rank Sector Weight
1 Healthcare 99.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RPTX
1
DELISTED
Repare Therapeutics
RPTX
$116M 5.6%
8,291,988
+2,433,212
+42% +$28.7M
MLTX icon
2
MoonLake Immunotherapeutics
MLTX
$1.62B
$114M 5.52%
+21,751,284
New +$137M
RCUS icon
3
Arcus Biosciences
RCUS
$3.55B
$100M 4.85%
3,960,948
– –
CGEM icon
4
Cullinan Oncology
CGEM
$1.08B
$96.3M 4.65%
7,509,059
+2,139,600
+40% +$24.3M
GHRS icon
5
GH Research
GHRS
$1.95B
$92.6M 4.47%
9,275,158
– –
MRUS
6
DELISTED
Merus
MRUS
$92.4M 4.46%
4,081,431
-53,640
-1% -$1.12M
KYMR icon
7
Kymera Therapeutics
KYMR
$8.8B
$81.5M 3.94%
4,138,758
+552,100
+15% +$12.9M
XOMA
8
DELISTED
Xoma
XOMA
$78.7M 3.8%
3,530,543
– –
RLAY icon
9
Relay Therapeutics
RLAY
$4.24B
$73.4M 3.55%
4,384,805
-145,800
-3% -$3.12M
CRNX icon
10
Crinetics Pharmaceuticals
CRNX
$8.85B
$68.6M 3.31%
3,678,947
+675,068
+22% +$13.5M
KURA icon
11
Kura Oncology
KURA
$826M
$58.7M 2.84%
3,203,783
– –
ACRS icon
12
Aclaris Therapeutics
ACRS
$743M
$55.5M 2.68%
3,976,543
– –
CTIC
13
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$53.3M 2.57%
8,929,690
– –
EQRX
14
DELISTED
EQRx, Inc. Common Stock
EQRX
$49.9M 2.41%
10,648,527
-1,377,043
-11% -$6.21M
XENE icon
15
Xenon Pharmaceuticals
XENE
$6.2B
$48.6M 2.35%
1,597,966
– –
IONS icon
16
Ionis Pharmaceuticals
IONS
$8.85B
$47.3M 2.28%
+1,276,574
New +$48.1M
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$1.73B
$45.3M 2.19%
2,356,934
-37,780
-2% -$629K
RVMD icon
18
Revolution Medicines
RVMD
$40.9B
$44M 2.12%
2,255,588
+445,039
+25% +$8.66M
ITOS
19
DELISTED
iTeos Therapeutics
ITOS
$39.7M 1.92%
1,929,201
+529,000
+38% +$12.6M
IDYA icon
20
IDEAYA Biosciences
IDYA
$3.5B
$38.6M 1.86%
2,794,859
+1,194,300
+75% +$13.3M
CNTA
21
DELISTED
Centessa Pharmaceuticals
CNTA
$33.6M 1.62%
6,894,345
+5,138,800
+293% +$32.9M
RLMD icon
22
Relmada Therapeutics
RLMD
$562M
$31.5M 1.52%
1,659,220
+11,820
+0.7% +$258K
CINC
23
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$31M 1.5%
1,644,393
-90,900
-5% -$1.74M
OLMA icon
24
Olema Pharmaceuticals
OLMA
$1.03B
$31M 1.5%
7,611,503
+200,000
+3% +$634K
FDMT icon
25
4D Molecular Therapeutics
FDMT
$526M
$28M 1.35%
4,007,413
+1,342,892
+50% +$13.1M
1
2 3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2022 Portfolio in Review

As of Q2 2022, BVF Inc held 87 positions worth $2.07B, down 17% from $2.5B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

BVF Inc deployed $142M of net new capital in Q2 2022, opening 6 new positions and adding to 22 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 21,751,284 shares worth $114M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $37.2M trimmed.

  • BVF Inc's largest Q2 2022 buy was MoonLake Immunotherapeutics: 21,751,284 shares worth $114M.
  • BVF Inc added most to Centessa Pharmaceuticals in Q2 2022, an estimated $32.9M increase.
  • BVF Inc's biggest Q2 2022 reduction was Protagonist Therapeutics, cutting an estimated $37.2M.
  • BVF Inc fully exited argenx in Q2 2022, selling an estimated $99.7M.
  • BVF Inc's ten largest holdings make up 44% of its $2.07B portfolio in Q2 2022.
  • BVF Inc opened 6 new positions and closed 8 in Q2 2022.
  • BVF Inc's portfolio value fell 17% quarter-over-quarter to $2.07B.

Based on BVF Inc's 13F filing for Q2 2022, filed 15 Aug 2022.